WELL Health Reports Q3 Revenue Growth, Reaffirms EBITDA Guidance
WELL Health reported revenue of $407.4 million, up 12% year over year, and adjusted EBITDA of $50.9 million, above consensus. It reaffirmed fiscal 2026 adjusted EBITDA guidance of $185 million to $195 million and updated its revenue outlook to approximately $1.58 billion.
Haywood Securities analyst Gianluca Tucci maintained a 'Buy' rating and an $8.00 price target on WELL Health Technologies on November 10, 2026, following the company's third-quarter performance. WELL reported revenue of $407.4 million, a 12% year-over-year increase, and an Adjusted EBITDA of $50.9 million, which exceeded consensus estimates. The analyst highlighted the company's Canadian clinic operations as a primary earnings driver and noted that a potential sale of U.S. assets could provide further shareholder value.
Management reaffirmed its fiscal 2026 Adjusted EBITDA guidance of $185 million to $195 million and updated its revenue outlook to approximately $1.58 billion.